BACKGROUND & AIMS:
We investigated whether serum trough levels of vedolizumab, a humanized monoclonal antibody against integrin a4b7, during the induction phase of treatment can determine whether patients will need additional doses (optimization of therapy) within the first 6 months.
METHODS:
We conducted an observational study of 47 consecutive patients with Crohn's disease (CD; n [ 31) or ulcerative colitis (UC; n [ 16) who had not responded to 2 previous treatment regimens with antagonists of tumor necrosis factor and were starting therapy with vedolizumab at 2 hospitals in France, from June 2014 through April 2016. All patients were given a 300-mg infusion of vedolizumab at the start of the study, Week 2, Week 6, and then every 8 weeks; patients were also given corticosteroids during the first 4-6 weeks. Patients not in remission at Week 6 were given additional doses of vedolizumab at Week 10 and then every 4 weeks (extended therapy or optimization). Remission at Week 6 of treatment was defined as CD activity score below 150 points for patients with CD and a partial Mayo Clinic score of <3 points, without concomitant corticosteroids, for patients with UC. Blood samples were collected each week and serum levels of vedolizumab and antibodies against vedolizumab were measured using an enzyme-linked immunosorbent assay. Median trough levels of vedolizumab and interquartile ranges were compared using the nonparametric Mann-Whitney test. The primary objective was to determine whether trough levels of vedolizumab measured during the first 6 weeks of induction therapy associated with the need for extended treatment within the first 6 months.
RESULTS:
Based on response to therapy at Week 6, extended treatment was required for 30 of the 47 patients (23 patients with CD and 7 patients with UC). At Week 2, trough levels of vedolizumab for patients selected for extended treatment were 23.0 mg/mL (interquartile range, 14.0-37.0 mg/mL), compared with 42.5 mg/mL in patients who did not receive extended treatment (interquartile range, 33.5-50.7; P [ .15). At Week 6, trough levels of vedolizumab <18.5 mg/mL were associated with need for extended therapy (100% positive predictive value, 46.2%; negative predictive value; area under the receiver operating characteristic curve, 0.72) within the first 6 months. Among patients who required extended treatment at Week 10, all of those with trough levels of vedolizumab <19.0 mg/mL at Week 6 had achieved clinical remission 4 weeks later (secondary responders).
I
n recent years, new biologic agents have been developed in inflammatory bowel diseases (IBD), both in Crohn's disease (CD) and ulcerative colitis (UC). Vedolizumab (VDZ) is a humanized monoclonal antibody that targets the a4b7 integrin exclusively, and modulates inflammation in the gastrointestinal tract without inducing the systemic immunosuppression. VDZ was approved by the Food and Drug Administration and the European Union European Medicines Agency in 2014, in patients with UC and CD who have not responded adequately to 1 or more standard therapies (corticosteroids, immunomodulators, or tumor necrosis factor [TNF] blocker medications).
1,2 In France, its indication is restricted to patients with IBD who are contraindicated to, or who did not tolerate, or who have previously failed anti-TNF agents. In the pivotal randomized trials (GEMINI 1, 2, and 3), [3] [4] [5] patients were treated by infusion with 300 mg of VDZ at weeks W0, W2, and W6 (induction phase), and then in case of response at W6 an infusion every 8 weeks (maintenance phase). In case of absence of response at W6, optimization of VDZ is considered and an additional infusion of VDZ at W10 and every following 4 weeks.
Numerous data have been accumulated on the usefulness of measurement of residual serum trough levels of infliximab 6 or adalimumab, 7 especially for predicting loss of response, or, inversely, for predicting sustained response. Several decisional trees based on therapeutic drug monitoring, including drug trough levels and specific antidrug antibodies, have been proposed to help clinician decision making regarding early drug optimization, switching drugs, maintenance dose, or deescalation of the treatment. [6] [7] [8] Predicting loss of response in patients with moderate to severe IBD could impact disease management, and subsequently the natural history of the disease, including the need for surgery.
To date, no clinical study has specifically investigated the value of trough level of VDZ (TLV) during induction therapy with VDZ for predicting long-term remission or the need for drug optimization. In the GEMINI 1 and 2 trials, VDZ trough levels measured during the induction phase were reported higher in responders when compared with those in nonresponders. 3, 4 We aimed to assess the performance of serum trough levels of VDZ to predict the need for drug optimization with VDZ within the first 6 months.
Methods

Population Study
All patients with IBD (CD and UC) who had failed 2 lines of anti-TNF and in whom VDZ treatment was initiated according to health ministry indication for VDZ in France were consecutively enrolled in the present prospective study. All patients were followed in the French University Hospitals of Saint-Etienne and Lyon, from June 2014 to April 2016. No concomitant immunosuppressor was prescribed and all patients were taking corticosteroids during the first 4-to-6-week induction phase with VDZ. All the patients received a 300-mg infusion of VDZ at W0, W2, W6, and then every 8 weeks. If there was no clinical response at W6, the patients were reviewed during a supplementary physician visit at W10 and received an additional dose of 300-mg VDZ at W10 in case of lasting nonresponse, followed by an infusion of VDZ every 4 weeks. VDZ optimization following the same schedule was performed during the maintenance phase in case of loss of response. Patients who were followed <10 weeks after induction VDZ therapy were excluded from analysis.
Definitions
For CD, sustained clinical remission was defined as a Crohn's Disease Activity Index score <150 points, and for UC as a partial Mayo Clinic score <3 points without concomitant corticosteroids and without need for VDZ optimization within the 6-month period of follow-up. In CD, lack of clinical response was defined as Crohn's Disease Activity Index >220 points with a fecal calprotectin >250 mg/g of stool, and in patients with UC by a total Mayo Clinic score >4 points with an endoscopy score >1 point warranting a dose optimization of VDZ or a switch to another treatment or even requiring surgery.
Primary responders were defined as patients who achieved a clinical remission at W6 of the treatment, and who do not need an additional VDZ infusion at W10. In case of partial response occurring from W6 to W10, the patients did not receive VDZ infusion at W10 and were considered as slow responders and not as nonresponders. Secondary responders were defined as patients who experienced a clinical remission after optimization started at W10. Responders were defined as primary and secondary responders. Nonresponders were defined as patients who had no primary or secondary response to therapy. A sustained response was defined as a primary response maintained during at least the first 6-month period with no need for optimization.
Measurement of Vedolizumab Serum Trough Levels and Management of Patients
VDZ TLVs and anti-VDZ antibodies were quantified using a specific biotinylated antibody directed against the idiotype of VDZ, and a biotinalyted VDZ against anti-VDZ antibody (LISA-TRACKER Duo Vedolizumab; Theradiag, France) (Supplementary Material). The assay range for VDZ trough levels is between 2 mg/mL and 60 mg/mL. Bridging drug-sensitive enzyme-linked immunosorbent assay was used to quantify antidrug antibody. The assay range for anti-VDZ is between 35 ng/mL and 500 ng/mL. The enzyme-linked immunosorbent assay used in the present study is a drug-sensitive assay. Antibodies against VDZ are defined as positive only in patients with undetectable VDZ levels. In patients with detectable serum VDZ levels, any Ac anti VDZ assay was considered as inconclusive.
All samples and results were collected and analyzed in a blinded fashion until the end of the study. Thus, the decision of management of the patients included was let at the discretion of the physician in charge of the patients and was based exclusively on clinical and biologic findings, including serum C-reactive protein and fecal calprotectin levels.
Statistical Analysis
The primary objective was to investigate the value of the TLVs monitored during the induction phase, as potential predictors of drug optimization within the first 6 months in patients with IBD requiring starting VDZ therapy. Qualitative variables were reported as numbers and percentages. Quantitative variables were reported as median value with their interquartile ranges from 25% to 75%. Receiver operating characteristic (ROC) curves analyses were performed to identify the best cutoff points of TLV at W2 and W6, which could predict the drug optimization at W10, secondary response after optimization at W10, and the need for optimization within 6 months. Median values of quantitative data were compared using the Mann-Whitney U test.
Results
Main Characteristics of the Population Study
Fifty-one consecutive patients were treated with VDZ from June 2014 to April 2016 (Figure 1 ), at the University Hospitals of Saint-Etienne and Lyon, France. Four patients were excluded because of a too short follow-up period (<10 weeks): 3 patients experienced an adverse event during this period (intestinal obstruction, nonarteritic anterior ischemic optic neuropathy, infection), and 1 patient was lost to follow-up (moved to another area in France). Thus, 47 patients were analyzed, including 27 (57.40%) primary responders, 15 (31.90%) secondary responders, and 5 (10.60%) nonresponders despite drug optimization. Among them, 30 patients (63.80%) needed drug optimization within the first 6 months. No patient was a slow responder. Table 1 shows the main characteristics of the population study and characteristics of patients who needed optimization within the first 6 months (n ¼ 30) compared with sustained primary responders (n ¼ 17). Of the 47 patients (median age, 37 years; interquartile range, 29-48), there were 26 (55.60%) women, 31 (66%) with CD, mainly with a phenotype L3 (51.10%), B2 (29.80%), or B1 (23.40%), according the Montreal classification. 9 About one-third of the patients with CD were diagnosed before 17 years old (A1, 10 of 31). Most of the patients with UC had an extensive colitis (E3, 14 of 16). About two-thirds of patients had been previously treated with steroids, and 15 patients with CD (48.40%) and 5 patients with UC (31.20%) had been under immunosuppressors (mainly thiopurines).
Comparison Between Patients Who Needed Drug Optimization Within 6 Months and Those Achieving a Sustained Remission
The characteristics of patients who needed drug optimization within 6 months were compared with those in patients who achieved a sustained remission under VDZ maintenance (Table 1 ). There was no significant difference between these 2 subgroups regarding age, sex ratio, perianal disease, previous treatments, and response after drug optimization. Five out of 17 patients (29.4%) who achieved a sustained remission under VDZ from the induction phase further needed drug optimization (after the first 6 months), at a median time of 31 weeks (29-32), regaining in 3 cases out of 5 a secondary response to therapy. In patients with CD, there was a higher proportion of patients in the drug-optimized subgroup (76.7%) compared with that of sustained remission (47.1%; P ¼ .06).
At W2, TLVs were identical in the 2 latter subgroups 
Receiver Operating Characteristic Curve Analyses
The performances of TLVs measured at W2 to predict the need for drug optimization at W10, the need for drug optimization within the first 6 months under VDZ, and to predict the occurrence of a secondary response to VDZ subsequent to drug optimization at W10, overall sustained response (with or without need for drug optimization), and overall clinical response in the whole cohort, are reported in Figure 3 with each of the corresponding ROC curves.
Under the cutoff point of 24.5 mg/mL for TLV measured at W2, all patients needed drug optimization within 6 months (positive predictive value [PPV], 100%; overall accuracy, 0.60). Among patients who needed drug optimization at W10, a TLV <35.5 mg/mL measured at W2 was highly associated with the achievement of a secondary response to VDZ, occurring in all patients (accuracy, 0.80; area under the ROC [AUROC], 77.1% [53.0%-100.0%]). Overall, all responders (primary and secondary responders) to VDZ had a TLV <36.0 mg/mL at W2 (PPV, 100%; accuracy, 0.70; AUROC, 72.2%; 95% confidence interval, 55.2%-89.2%). According to these results, TLV measured at W2 that was associated with the occurrence of a sustained remission in patients with IBD at W24 ranged from 24.5 to 36.0 mg/mL (PPV, 100%; accuracy, 0.6-0.7).
The corresponding performances of TLVs measured at W6 and respective ROC curves are reported in Figure 4 . At W6, a TLV <18.5 mg/mL was associated with the need for drug optimization within 6 months under VDZ (PPV, 100%; negative predictive value, 46.2%; accuracy, 0.6; AUROC, 71.8% [48.1%-95.5%]). Among these patients who needed drug optimization at W10, TLV <19.0 mg/mL measured at W6 was associated with the achievement of a secondary response in 100% of the cases (accuracy, 0.7; AUROC, 71.7% [46.9%-96.4%]). In contrast and despite a low AUROC (57.1% [18.5%-95.7%]), a TLV >27.5 mg/mL at W6 was associated with the achievement of a sustained response in 90% of patients with IBD (sensitivity, 64.3%; accuracy, 0.7).
Trough Levels of Vedolizumab and Antivedolizumab Antibody During Follow-Up
Curves of the median TLV and their interquartile ranges over the time are reported for responders versus nonresponders (Supplementary Figure 1) , and for primary responder, secondary responder, and nonresponder patients with IBD ( Supplementary Figure 2) Table 1 ). Monitoring the TLVs during the maintenance phase revealed a decrease of them, both in primary (1-25 mg/mL) and in secondary (10-25 mg/L) responders (Supplementary Figure 1) . Similar evolution of the median TLVs over the time of VDZ therapy was observed between responders and nonresponders (Supplementary Figure 2) .
Impact of Drug Optimization on Trough Levels of Vedolizumab
TLVs before and after optimization (at W10 or later) were monitored to perform paired analyses across subgroups. Thus, there was no biologic difference after optimization in primary responders (P ¼ .94), secondary responders (P ¼ .40), nonresponders (P ¼ 1.0), sustained primary responders (P ¼ .44), or in patients who needed optimization within 6 months (P ¼ .78).
Discussion
This is one of the rare studies that have reported VDZ trough levels over time, and the only study that has specifically investigated the potential of TLV as predictor or associated factor of response to therapy, response to drug optimization in patients with IBD. First data on the pharmacokinetics of VDZ came from a randomized phase II study assessing 3 dosing groups of VDZ (2 mg/kg, 6 mg/kg, and 10 mg/kg) monitored on Days 1, 15, 29, and 85. 10 Serum VDZ concentrations increased in a dosedependent manner with escalating doses, and the mean elimination half-life was estimated to be around 15-22 days. 10 In the phase III GEMINI trials, additional pharmacokinetic data have reported TLV after induction and during maintenance VDZ therapy with higher TLVs at the end of induction at Week 6 (TLVs, 27.9 AE 15.5 mg/mL) reaching a steady state concentration of 11.2 AE 7.2 mg/ mL under maintenance VDZ therapy with 300 mg every 8 weeks, and reaching highest concentrations (38.3 AE 24.4 mg/mL) under VDZ 300 mg every 4 weeks. 4 Finally, VDZ levels were higher in responders than in nonresponders in these trials. 3, 4 These findings are in accordance with those from the present study, because regularly monitoring TLVs shows higher values of TLVs during the induction phase as soon as W2 but also at W6 compared with those measured during the maintenance phase. In contrast, in our study TLVs did not significantly differ in responders versus nonresponders, both during induction and maintenance regimens with a trend toward being higher in nonresponders.
It is important to note that in CD, GEMINI 3 trials showed that response rate at W14 was higher than that observed at W6 without need for optimization within this laps time, which supports the existence of slow responders. In our clinical practice, we estimated that absence of any clinical improvement during the W6-W10 period was witness of nonresponse and thus need for optimization. Conversely, patients could be considered as slow responders at W10, in case of improvement of disease activity score without reaching clinical remission. Thus, slow responders would not be optimized but no patient experienced this situation in the present study ( Figure 1 ).
More interestingly, we report here that a low TLV as soon as at W2 (<24.5 mg/mL) but also at the end of the induction therapy at W6 (<18.5 mg/mL) was associated with the need for drug optimization within 6 months in all patients. In addition, all patients with a TLV <19.0 mg/mL at W6 regained a secondary response after optimization at W10. These outcomes may be clinically relevant helping to identify early patients needing VDZ optimization. Thus, low TLVs measured at W6 could represent a novel surrogate pharmacologic marker of nonresponse under VDZ therapy and may help clinicians in decision-making, avoiding an inappropriate delay before drug optimization, or allowing them to consider an early switch toward another treatment.
In the present study, we propose, for the first time, a threshold of TLV during the induction phase with VDZ therapy capable of identifying patients at high risk of drug optimization within the 6 months of follow-up with an excellent PPV despite a relatively low sensitivity and overall accuracy.
As previously reported in patients with severe active UC under infliximab, in whom significant infliximab stool release was detected and associated with a lack of response to therapy, 11 it would be also interesting to monitor in further studies the concentrations of VDZ in stool.
Of the 1434 patients issued from the GEMINI trial, anti-VDZ antibodies were detected in 56 (3.70%) Figure 4 . ROC of vedolizumab trough levels at W6 as predictors for response to therapy and for drug optimization. AUC, area under the curve.
patients during the 52 weeks of follow-up. 4 Using the same method of detection of these specific antibodies, no patient in our cohort has developed anti-VDZ antibody within the period of follow-up, suggesting that immunogenicity of VDZ should be low. However, this hypothesis must be confirmed using a tolerant drug assessment.
We acknowledge that the main limitation of our study is the small size sample of our studied population limiting the interpretation of the subgroups analysis. As precise in methods, our results were focused on patients who had previously experienced failure with 2 lines of anti-TNF. This is because of the indication of VDZ in France. Hence, no generalizability can be done specifically for patients with IBD who are naive or in failure with 1 line of anti-TNF. Moreover, the fact that the 95% confidence interval of all predictive ROC actually crosses the 0.5 point could suggest that predictive performances of TLV were low. This is probably explained by a low statistical power caused by the small size population on the one hand, and by the fact that VDZ has a targeted action that is dependent of the levels of a4b7 integrin expression on the other hand. Further measurement of this integrin expression is warranted to refine our values. However, this prospective study has been conducted in a real-life basis and that represents its major strength. Our present findings should be confirmed by further prospective and larger studies.
Conclusions
Low trough levels of VDZ at W6 seem to be associated with drug optimization within 6 months leading to regaining a secondary clinical response in all patients. Further studies, such as independent cohort of patients, are needed to confirm the potential usefulness of monitoring TLV to predict the disease course of patients with IBD under maintenance therapy with VDZ, to validate our threshold values, and to explain mechanisms of response or nonresponse according to VDZ levels. 
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